Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05588999
Other study ID # CMHAtd-ETH-38-Derm-22
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date March 1, 2022
Est. completion date August 31, 2022

Study information

Verified date October 2022
Source Combined Military Hospital Abbottabad
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Verrucae plantaris (plantar warts) are a frequent cutaneous lesion of the plantar portion of the foot caused by the human papillomavirus (HPV) (HPV).Although HPV is ubiquitous in our environment, cellular and humoral immune responses typically prevent it from spreading or eliminate it. Warts can be painful and can lead to other difficulties, but there are some populations that are at a higher risk of getting HPV because they encounter the virus more frequently. In addition to infecting other people, HPV can also spread to other locations in the area. While reducing exposure to risk factors can help prevent plantar wart infection, HPV's widespread nature makes it difficult for such efforts to be effective. It has been shown in research that plantar warts can spread from person to person through just physical contact with the sores. Warts are more common in people with HPV because the virus disrupts the epithelial barrier. There are over a hundred different forms of the HPV virus, so even though some warts go away on their own after a few years, others may need medical attention. Warts, according to a number of studies, are extremely common (affecting around 10% of the population) all over the world. More cases of HPV infection have been observed among people under the age of 30, compared to those beyond the age of 30. The estimated prevalence in the United States is between 10% and 20%. However, people with compromised immune systems and those who work with meat are disproportionately at risk. The cancerous transformation of warts is quite rare. Even while verrucous carcinoma, a malignant form of wart development, is possible, it seldom spreads and only causes localised tissue loss. Plantar warts are treated in a manner that takes into account the patient's symptoms, personal preferences, and financial situation. Even though there are several therapy options, none of them are particularly effective, and relapses are common after any treatment. As a result, the most accessible and least distressing treatment option should be prioritised. Since salicylic acid can be used by the patient at home and does not require a doctor's prescription, it is often regarded a first-line therapy for the common wart. It can be as high as 70% effective in curing the disease. Other effective therapies for plantar warts include cryotherapy, retinoic acid, podophyllin, topical 5-fluorouracil, interferon, and imiquimod. Salicylic acid, in conjunction with cryotherapy, has shown therapeutic efficacy in patients with only foot warts, according to a single prior study. Patients who were given cryotherapy in this trial had a 58% success rate at recovery, whereas those given salicylic acid had a 41% success rate. Hover, there is no discernible statistical difference. The purpose of this study was to compare the effectiveness of cryotherapy alone against cryotherapy plus salicylic acid dressing for planter warts, keeping in mind the prevalence of treatment for plantar warts and the lack of a well-established, practically applicable, and reliably preventative method in our local population.


Recruitment information / eligibility

Status Completed
Enrollment 70
Est. completion date August 31, 2022
Est. primary completion date August 31, 2022
Accepts healthy volunteers No
Gender All
Age group 15 Years to 40 Years
Eligibility Inclusion Criteria: - Patients having aged between 15 to 40 years - Patients diagnosed with planter warts on toe foot based on clinical and physical examination ,Patients with no history of treatment previously - Patients of either gender Exclusion Criteria: - Patients with impaired healing (such as from diabetes or peripheral vascular disease) - Immunosuppressed patients - Patients taking immunosuppressant drugs (such as oral corticosteroids) - Patients with neuropathy - Patients receiving renal dialysis - Patients unable to give informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Cryotherapy Alone
Patients in Group A were subjected to Cryotherapy Alone with liquid nitrogen and received maximum of four treatments given two to three weeks apart . The liquid nitrogen was applied with a spray or a probe
Combination Product:
Cryotherapy plus Salicylic Acid
Patients in Group B were subjected to cryotherapy plus with 50% salicylic acid to be properly applied for a maximum of eight weeks The liquid nitrogen was applied with a spray or a probe

Locations

Country Name City State
Pakistan Cmh Abbottabad Abbottabad Khyber Pakhtunkhwa

Sponsors (1)

Lead Sponsor Collaborator
Combined Military Hospital Abbottabad

Country where clinical trial is conducted

Pakistan, 

Outcome

Type Measure Description Time frame Safety issue
Primary effectiveness of cryotherapy with liquid nitrogen alone and cryotherapy with 50% salicylic acid for the treatment of plantar warts calculated through clinical improvement effectiveness assesed by %clinical improvement=(present % tissue distruction + baseline % tissue destruction)100 12 weeks
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05324904 - Intralesional Vitamin D3 Versus Intralesional Acyclovir in Treatment of Plantar Warts N/A
Completed NCT00328991 - Clinical Trial Evaluating Efficacy of Duct Tape for Treatment of Warts N/A
Completed NCT05592041 - Studying of Natural Constituents' Treatment of Plantar Warts Early Phase 1
Completed NCT05115669 - Safety & Effectiveness of Wortie Freeze Plus in Common and Plantar Warts N/A
Recruiting NCT06261684 - Intralesional Acyclovir Versus Cryotherapy in the Treatment of Plantar Warts. A Randomized Controlled Trial. Phase 2/Phase 3
Not yet recruiting NCT05057663 - Intralesional Treatment of Plantar Wart N/A
Recruiting NCT02151630 - Pyruvic Acid Versus Salicylic Acid Preparation in Treatment of Plantar Warts Phase 2/Phase 3
Withdrawn NCT04823845 - Plantar Wart Treatment Using Adapalene Gel Early Phase 1
Completed NCT01536834 - Safety & Performance Study of Verruca Treatment Device N/A
Recruiting NCT05488860 - Piezoelectric Drived Microneedling in Treating Refractory Skin Diseases N/A
Recruiting NCT05520658 - Evaluation of the Efficacy of Intralesional Injection of Combined Digoxin and Furosemide Versus 5 - Fluorouracil in Treatment of Plantar Warts N/A
Not yet recruiting NCT04654091 - Cryotherapy VS. Nitric-zinc Complex in the Treatment of Plantar Warts. N/A
Not yet recruiting NCT05599971 - Intralesional Injection of Combined Digoxin and Furosemide Versus 5-Flurouracil in Plantar Warts N/A
Not yet recruiting NCT05198180 - Treatment of Plantar Warts Phase 3
Recruiting NCT06214559 - Evaluate the Effectiveness and the Safety of a Medical Device in the Treatment of Common Warts and Plantar Warts. N/A
Recruiting NCT03977753 - Randomized, Placebo-controlled, Double Blind Study to Evaluate the Efficacy of 2LVERU®JUNIOR and 2LVERU® on the Treatment of Warts Phase 4
Completed NCT03183765 - Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts Phase 4